Innovent Biologics AGM approves all resolutions with overwhelming support

Innovent Biologics Inc. (HKEX: 1801) announced the successful passage of all resolutions at its Annual General Meeting held on June 25, 2025. Key approvals include the re-election of Dr. De-Chao Michael Yu as an executive Director (with 96.82% votes for), Dr. Charles Leland Cooney (99.13% votes for) and Mr. Gary Zieziula (99.83% votes for) as independent non-executive Directors. Shareholders also authorized the Board to fix the remuneration of the Directors and re-appointed Deloitte Touche Tohmatsu as auditor, again with over 99% approval. A general mandate was granted to the Directors to buy back shares (99.93% for) and to issue additional shares of the Company (79.08% for). Additionally, shareholders approved the grant of 2,754,000 restricted shares to Dr. De-Chao Michael Yu (82.72% for). As of the AGM date, Innovent's total number of shares in issue was 1,653,402,392.